Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

Thymic and bone marrow outputs were evaluated in 13 sequential samples of 68 multiple sclerosis patients who initiated alemtuzumab and were clinically followed for 48  months. Three months after alemtuzumab infusions, the levels of new T lymphocytes were significantly reduced, but progressively increased reaching the highest values at 36 months, indicating the remarkable capacity of thymic function recovery. Newly produced B cells exceeded baseline levels as early as 3 months after alemtuzumab initiation.

Source: Journal of Neuroimmunology - August 7, 2023 Category: Allergy & Immunology Authors: Alessandra Sottini, Virginia Quaresima, Mos è Barbaro, Lucia Moiola, Massimo Filippi, Maria Malentacchi, Marco Capobianco, Marco Puthenparampil, Paolo Gallo, Eleonora Cocco, Jessica Frau, Mauro Zaffaroni, Clara Guaschino, Chiara Stampatori, Chiara Mancin Source Type: research